期刊文献+

宫颈癌术后保护骨髓调强放疗的剂量学优势 被引量:1

Dosimetric advantages of bonemarrow-sparing intensity modulated radiotherapy for cervical cancer after hysterectomy
下载PDF
导出
摘要 目的对比分析保护骨髓调强放疗(bone marrow sparing-intensity modulated radiation therapy,BMS-IMRT)与普通调强放疗(intensity modulated radiation therapy,IMRT)在宫颈癌术后患者中的剂量学参数,为BMS-IMRT的临床应用提供一定理论依据。方法10例宫颈癌术后患者纳入研究,针对每例患者分别制作BMS-IMRT与IMRT两种计划,收集计划靶区(planning target volume,PTV)与危及器官(organs at risk,OARs)的相关剂量学指标进行统计学分析。结果BMS-IMRT计划PTV的平均Dmax与Dmean均高于IMRT计划,且HI劣于IMRT计划(P<0.05),BMS-IMRT计划中平均的骨髓V10、V20、V30、V40均低于IMRT计划,股骨头Dmax低于IMRT计划(P<0.05),两种计划中直肠、膀胱的受照剂量比较差异均无统计学意义(P>0.05)。结论对于宫颈癌术后患者,BMS-IMRT相较于普通IMRT在保证治疗靶区覆盖的同时可降低骨髓的受照剂量,并不增加直肠与膀胱的受照剂量,理论上可降低血液学毒性的发生。 Objective The dosimetric parameters of bone marrow sparing-intensity modulated radiation therapy(BMS-IMRT)and conventional intensity modulated radiation therapy(IMRT)in patients with cervical cancer after hysterectomy were compared and analyzed,providing a theoretical basis for the clinical application of BMS-IMRT.Methods Ten patients with cervical cancer undergoing hysterectomy were selected to design BMS-IMRT and IMRT plans respectively,and the dosimetric indexes of the planning target volume(PTV)and organs at risk(OARs)were statistically analyzed.Results The mean value of Dmax and Dmean in BMS-IMRT group were higher than those in IMRT group and the homogeneity index(HI)of PTV in the BMS-IMRT group was inferior to that in IMRT group(P<0.05).The mean V10,V20,V30,V40 of bone marrow in BMS-IMRT group were lower than those in IMRT group,and the Dmax of femoral heads was also lower in the BMS-IMRT group than in IMRT group(P<0.05).The radiation dose of rectum and bladder in the two plans was not statistically significant(P>0.05).Conclusion BMS-IMRT can reduce the radiation dose of bone marrow while ensuring the coverage of PTV compared with the conventional IMRT in postoperative patients with cervical cancer and dose not increase the radiation dose of the rectum and bladder,theoretically reducing the occurrence of hematological toxicity.
作者 田磊 薛晓英 王艳强 肖志清 盖晓惠 TIAN Lei;XUE Xiao-ying;WANG Yan-qiang;XIAO Zhi-qing;GE Xiao-hui(Department of Radiotherapy, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China)
出处 《河北医科大学学报》 CAS 2021年第10期1210-1214,共5页 Journal of Hebei Medical University
基金 河北省医学科学研究课题(20200931)。
关键词 宫颈癌 保护骨髓 放射治疗 剂量学 Cervical cancer bone marrow sparing radiation therapy dosimetry
  • 相关文献

参考文献1

二级参考文献18

  • 1MELL L K, KOCHANSKI J D, ROESKE J C, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity- modulated pelvic radiotherapy [ J ] . Int J Radiat Oncol Biol Phys, 2006, 66(5): 1356-1365. 被引量:1
  • 2SMALL W, MELL L K, ANDERSON P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer [ J ] . Int J Radiat Oncol Biol Phys, 2008, 71(2): 428-434. 被引量:1
  • 3TAYLOR A, ROCKALL A G, REZNEK R H, et al. Mapping pelvic lymph nodes: guidelines for delineation in intensity- modulated radiotherapy [ J ] . Int J Radiat 0ncol Biol Phys, 2005, 63(5): 1604-1612. 被引量:1
  • 4VALE C, TIERNRY J F, STEWART L A, et al. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trims [ J ] . J Clin Oncol, 2008, 26(35): 5802-5812. 被引量:1
  • 5LONG H J, BUNDY B N, GRENDYS E C, et al. Randomized phase Ⅲ trial of cisplatin with or without topotecan in carcinoma of the uterine cervix [ J ] . J Clin Oncol, 2005, 23(21): 4626-4633. 被引量:1
  • 6MOORE D H, BLESSING J A, MCQUELLON R P, et al. Phase Ⅲ study of cisplatin with or without paelitaxel in stage ⅣB, recurrent, or persistent squamous cell carcinoma of the cervix [ J ] . J Clin Oncol, 2004, 22 (15): 3113-3119. 被引量:1
  • 7BRIXEY C J, ROESKE J C, LUJAN A E, et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies [ J ] . Int J Radiat Oncol Biol Phys, 2002, 54(5): 1388-1396. 被引量:1
  • 8YANG B, ZHU L, CHENG H, et al. Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: a systematic review and meta-analysis [J] .Radiat Oneol, 2012, 7: 197. 被引量:1
  • 9KLOPPL A H, MOUGHAN J, PORTELANCE L, et al. Hematologic Toxicity on RTOG 0418: a phase II study of post- operative IMRT for gynecologic cancer [ J ] . Int J Radiat Oncol Biol Phys, 2010, 78(3): 258. 被引量:1
  • 10MELL L K, SCHOMAS D A, SALAMA J K, et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and IMRT [ J ]. Int J Radiat Oncol Biol Phys, 2008, 70(5): 1431-1437. 被引量:1

共引文献18

同被引文献9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部